A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
about
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disordersCannabinoids for pediatric epilepsy? Up in smoke or real science?Evidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosisCurrent Therapeutic Cannabis Controversies and Clinical Trial Design IssuesMarijuana Legalization: Impact on Physicians and Public HealthPharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters.Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.Inhibition of fatty acid binding proteins elevates brain anandamide levels and produces analgesia.Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.Use of Fingolimod in the Management of Relapsing-Remitting Multiple Sclerosis: Experience from Latin AmericaClinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.Cannabinoid Receptors in the Central Nervous System: Their Signaling and Roles in Disease.Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.The influence of cannabinoids on generic traits of neurodegeneration.Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.Placebo effects in a multiple sclerosis spasticity enriched clinical trial with the oromucosal cannabinoid spray (THC/CBD): dimension and possible causes.Comprehensive Review of Medicinal Marijuana, Cannabinoids, and Therapeutic Implications in Medicine and Headache: What a Long Strange Trip It's Been ….Cannabinoids therapeutic use: what is our current understanding following the introduction of THC, THC:CBD oromucosal spray and others?Evaluation and Management of SCI-Associated Pain.Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex®): A Review in Multiple Sclerosis-Related Spasticity.Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial.Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis.Efficacy and safety of nabiximols (Sativex(®)) on multiple sclerosis spasticity in a real-life Italian monocentric study.Walking improvements with nabiximols in patients with multiple sclerosis.Drug-resistant MS spasticity treatment with Sativex(®) add-on and driving ability.Use of Cannabinoids for Spasticity and Pain Management in MS.A prospective observational study of problematic oral cannabinoid use.WEED: marijuana, medicine and neuroscience: history of the Alfred I. duPont-Columbia University Award.Efficacy and Tolerability of Phytomedicines in Multiple Sclerosis Patients: A Review.Pharmacotherapeutic considerations for use of cannabinoids to relieve pain in patients with malignant diseases.Patterns of medicinal cannabis use, strain analysis, and substitution effect among patients with migraine, headache, arthritis, and chronic pain in a medicinal cannabis cohort.Cannabinoids and agmatine as potential therapeutic alternatives for cisplatin-induced peripheral neuropathy.Upper motor neuron evaluation in multiple sclerosis patients treated with Sativex®
P2860
Q22299116-E5D04876-EC3A-46BB-868A-E21F79189A77Q26770299-1B4C20AE-8E83-4285-8888-8951635CF2BBQ26770823-F0BA94FE-C84E-4718-B16F-06D360DBE8F5Q28071794-FF78FB47-08FB-43B4-9628-3333E0A189D9Q28082785-EFA2DF52-D361-482C-BDE1-9F21F7A85D8EQ30250250-C67DBB43-44EA-4631-9A40-BAC8D29A9FCBQ34219132-18A2234E-D054-4EA5-AE50-A2128092A608Q34417710-90E839AA-DB8C-4158-BDE7-23C68CE2DD0DQ34642592-E51EB0D8-FF20-4520-B7B6-8C8A5B0214E1Q35140182-BE31368B-E35A-47F0-9BA4-3B66F8BCC80AQ35577414-7ADA19A8-4560-45C2-BB33-65851D0532D3Q35907969-ED3AEE0A-4033-4985-B73F-7179139F1922Q36157623-45197C7C-46AB-42BF-9B0D-C1B164BB854EQ36178329-A75CE7F3-E2F0-4F7B-A5AD-965D3CA38D08Q37512670-7EF4F70C-6B4B-49D6-9519-74177633E905Q37553341-5AB679D0-C038-4A5A-8DF2-02F3413E5C71Q38003185-36992FCF-3185-4E06-BD4C-2890407DB99DQ38003186-8FC35458-BC6E-4F99-B512-2627CF5D7B19Q38041231-B1FCFDA5-5E42-4099-ADF1-07BA20641937Q38156518-19BAE985-FB89-4B19-8F4C-2FCC9198EB1DQ38199658-A25C6EAE-E035-4B4F-A231-B015A037D7D9Q38261541-2E8C3254-C622-44C4-ADE2-8529247CB5B1Q38283173-BDB9C707-9EAD-4351-9F0B-98CDAC54EBB7Q38503842-D1921216-AD11-470F-9BEA-55F7B0D0E0E2Q38748394-D928F213-E478-4B31-AB79-5B2721418CC0Q38913057-7135340D-230D-444E-AB24-16352C907B41Q39178828-DEC975E8-E43B-46F5-8ED2-380033643D7FQ39200153-23D2B8AC-5606-41A8-BDF1-0F1A2B51C963Q39243714-042D9A4D-934A-49C5-A456-FEDFD8A3F77EQ40422912-4D72B920-9C6D-43E8-936B-DC8785107D3DQ40664257-A2D5B51E-D67D-41DF-A0F8-CB816BFD5A6AQ45824130-C9EC627E-5BD5-4000-8B30-E98D73ED34D7Q46968189-D02EE06F-FFEC-45D4-AC7D-10437F7B750AQ47219944-7631382A-D3CD-48CF-A40F-EC463E5B4942Q48045477-19ED3C15-9A5A-456A-AD6F-76D20E0126DCQ49834512-2CE3D90D-459E-47B0-961B-6AB56C1885A6Q54958903-29FACD3A-6D73-4EC0-98C4-B75D1499E050Q55333056-1A3A778F-8ED0-4F40-957A-61B8403C36EBQ55340197-9A936DC8-BF02-4B3F-943C-A02786E41D49Q57269575-2A274F2D-DC01-4F39-8A6B-727BCB8F94D2
P2860
A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@ast
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@en
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@nl
type
label
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@ast
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@en
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@nl
prefLabel
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@ast
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@en
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@nl
P2093
P2860
P356
P1476
A placebo-controlled, parallel ...... ng-term Sativex® (nabiximols).
@en
P2093
P2860
P304
P356
10.1177/1352458511419700
P577
2011-08-30T00:00:00Z